Guggenheim Reiterates Buy Rating for Grail Inc. on Galleri's Potential

Grail Inc. (GRAL) has been rated Buy by Guggenheim due to its potential for long-term value as a broad-based multi-cancer early detection test. The firm anticipates FDA approval for Galleri, the company's flagship product, and believes future data releases will address concerns raised by a recent trial's primary endpoint miss. Grail employs AI to identify and detect multiple deadly cancer types at earlier stages.